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for	 adverse	effects	 and	provide	advice	 about	 changes	 to	 treatment	 regimens	where	necessary;	 and	monitor	 for	
adverse	psychological	impacts.	However,	it	is	not	clear	how	often	patients	consult	in	primary	care,	both	in	terms	of	
new	 consultations	 and	 follow-up	 consultations.	 In	 addition,	 there	 are	 few	 data	 about	medications	 primary	 care	
clinicians	prescribe	for	acne	and	how	frequently	they	are	prescribed	to	an	individual	patient.	There	are	increasing	
concerns	 about	 the	 development	 of	 antibiotic	 resistance	 in	 acne,8	 and	 UK	 guidelines	 recommend	 restricting	
antibiotics	to	second	or	third	line	treatments	and	combining	oral	antibiotics	with	topical	treatments	such	as	benzoyl	
peroxide	(to	reduce	resistance),	or	retinoids	or	adapalene	(to	reduced	comedones).	6,7	


































































































the	 following	90	days.	 Figure	4	gives	a	graphical	 representation	of	which	ARMs	 (or	 combinations)	patients	were	
prescribed	at	baseline	and	in	the	following	90	days.	78,567	(46.9%)	patients	were	prescribed	no	ARMs	during	the	

















new	 acne	 consultation	 (no	 acne	 consultations	 or	 prescriptions	 in	 the	 preceding	 year)	 have	 a	 follow-up	 acne	
consultation	in	the	subsequent	year.	A	quarter	of	patients	with	a	new	acne	consultation	are	prescribed	no	ARMs	


















therefore	 may	 have	 included	 some	 out-of-hours,	 secondary	 care	 or	 spurious	 consultations	 as	 primary	 care	
consultations.	This	is	unlikely	to	have	been	a	frequent	occurrence,	but	our	consultation	rates	and	follow-up	rates	






















































first	 line,	 and	 about	 20%	 of	males	 and	 a	 quarter	 of	 females	were	 prescribed	 topical	 antibiotics	 first	 line.
18
	 The	










































antibiotic	 and	 a	 topical	 agent.	 Therefore,	 in	 total,	 just	 over	 three-quarters	 of	 initial	 acne	 therapy	 included	 an	









the	 development	 of	 respiratory	 tract	 infections.
29
































































































8	to	11	 12	to	18	 19	to	29	 30+	
Within	30	days	 72	(7.6)	 3,423	(10.0)	 1,842	(12.9)	 1,085	(15.3)	 6,422	(11.3)	
31	to	60	days	 107	(11.4)	 6,301	(18.3)	 2,737	(19.1)	 1,406	(19.9)	 10,551	(18.6)	
61	to	90	days	 90	(9.5)	 4,940	(14.4)	 2,171	(15.2)	 1,062	(15.0)	 8,263	(14.6)	
91	days	to	6	
months	
248	(26.3)	 8,091	(23.5)	 3,421	(23.9)	 1,643	(23.2)	 13,403	(23.6)	
6	months	to	1	
year	
426	(45.2)	 11,644	(33.9)	 4,138	(28.9)	 1,886	(26.6)	 18,094	(31.9)	













N	 %*	 %#	 N	 %*	 %#	 N	 %*	 %#	
No	ARM	 44,809	 26.7	 -	 113,131	 67.5	 -	 78,567	 46.9	 -	
Oral	antibiotic	
alone	





39,529	 23.6	 32.2	 11,004	 6.6	 20.2	 16,806	 10.0	 18.9	
Topical	non-
antibiotic	alone	




9,168	 5.5	 7.5	 5,711	 3.4	 10.5	 12,009	 7.2	 13.5	
Oral	antibiotic	+	
topical	antibiotic	
4,671	 2.8	 3.8	 3,666	 2.2	 6.7	 11,215	 6.7	 12.6	
Co-cyprindiol	
alone	
4,014	 2.4	 3.3	 2,433	 1.5	 4.5	 3,987	 2.4	 4.5	
Co-cyprindiol	+	
any	topical	agent	
793	 0.5	 0.6	 564	 0.3	 1.0	 2,265	 1.4	 2.5	
Oral	isotretinoin	
alone	
15	 0.0	 0.0	 36	 0.0	 0.1	 47	 0.0	 0.1	
Oral	isotretinoin	+	
other	ARM	
2	 0.0	 0.0	 8	 0.0	 0.0	 98	 0.1	 0.1	
Other	combination	 1,906	 1.1	 1.6	 977	 0.6	 1.8	 3,371	 2.0	 3.8	
Total	 167,573	 100	 100	 167,573	 100	 100	 167,573	 100	 100	
*	Proportion	of	total	
#	Proportion	of	those	who	were	prescribed	an	ARM	
	
	 	
	Table	4	–	Quantity	of	ARM	medication	prescribed	per	prescription	
Medication	 Quantity	per	
prescription	–	
median	(IQR)	
Equivalent	
number	of	days	
(approximately)*	
Oral	antibiotics	
Oxytetracycline	 112	(112,	120)	 28	
Doxycycline	 50	(28,	56)	 25	
Lymecycline	 56	(28,	56)	 56	
Minocycline	 56	(56,	56)	 28	
Other	tetracyclines	 112	(56,	112)	 28	
Erythromycin	 100	(42,	112)	 25#	
Oral	hormonal	
Co-cyprindiol	 63	(63,	126)	 84	
Topical	
Clindamycin	 50	(30,	50)	 50	
Erythromycin	 50	(50,	50)	 50	
Clindamycin/BPO	 25	(25,	50)	 50	
Erythromycin/retinoid	 30	(25,	47)	 30-60	
BPO	 40	(40,	60)	 40-80	
BPO/hydroxyquinolone	 50	(25,	50)	 33-50	
Azelaic	acid	 30	(30,	30)	 30-60	
Retinoids	 60	(30,	60)	 60-120	
Adapalene	 45	(45,	45)	 90	
Adapalene/BPO	 45	(45,	45)	 90	
*For	topical	agents	a	rough	guide	of	0.5g	(equivalent	to	the	size	of	two	
palm	areas)	per	application	was	used	
#	87%	of	erythromycin	tablets	were	250mg	
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Figure	1:	Acne	consultation	rates	by	age	and	gender:	2004	–	2013	
	
Figure	2:		Oral	acne	related	medication	prescribing:	2004	–	2013	
	
	
	Figure	3:	Topical	acne	related	medication	prescribing:	2004	–	2013	
	
	
	 	
	Figure	4:	Sankey	diagram	of	acne	related	medication	(ARM)	prescribing	at	an	index	consultation	and	over	the	
subsequent	90	days	
	
